dQ&A First Look – Awiqli
How will once-weekly basal insulin reshape diabetes care?
With the U.S. launch of Novo Nordisk’s Awiqli on the horizon, the diabetes industry is entering one of its most significant shifts in decades. Clinical trials have demonstrated efficacy and safety—but the biggest commercial questions remain unanswered:
- Will patients embrace once-weekly insulin?
- How easy is onboarding and dose titration in the real world?
- Does weekly dosing reduce the burden of diabetes management?
- Which patients are the best candidates?
- What barriers could limit long-term adoption?
dQ&A Has Answers
dQ&A First Look Awiqli delivers the industry's first real-world patient insights into the once-weekly basal insulin experience.
Drawing on qualitative interviews, quantitative research, and real-world clinical data from Canadian patients already using Awiqli, this insights package provides an early view of how patients are adapting to a fundamentally new treatment paradigm—and what it could mean for the future of the basal insulin market.
Whether you're developing insulin therapies, diabetes technology, connected health solutions, or patient support programs, First Look Awiqli will help you anticipate market shifts before once-weekly insulin reaches widespread adoption.
Contact Us to Learn MoredQ&A First Look Awiqli
The First Look series helps organizations understand what really happens when innovative diabetes therapies reach everyday clinical practice.
Our latest edition, “First Look Awiqli” delivers actionable market intelligence to anticipate change, identify commercial opportunities, and make smarter decisions ahead of the U.S. launch.
What makes First Look Awiqli different?
- Primary research from early adopters
- Real-world patients and real-world insights from routine clinical practice
- Reveals adoption, behavior, and experience
- Supports commercial decision-making
- Answers the question: “Will patients and providers embrace Awiqli?”
A Comprehensive View of the Real-World Awiqli Experience
First Look Awiqli integrates qualitative interviews, quantitative surveys, and real-world clinical data to provide a complete picture of the user experience.
Qualitative Interviews
In-depth interviews with current Awiqli users uncover motivations, emotional reactions, treatment journeys, onboarding experiences, and unmet needs.
Quantitative Survey
A survey of current Awiqli users quantifies the patient experience and validates qualitative findings across a broader population.
Real-World Clinical Data
De-identified electronic health record (EHR) data provides objective evidence on treatment patterns and clinical outcomes.
Together, these data sources deliver comprehensive, evidence-based insights into how Awiqli performs in everyday clinical practice.
Early Answers to
Critical Commercial Questions
- What motivates patients to start taking once-weekly insulin?
- What value does Awiqli deliver beyond fewer injections?
- How easy is onboarding and dose titration?
- How does once-weekly insulin influence glucose monitoring behaviors?
- What is the real-world hypoglycemia experience?
- Does weekly dosing reduce the burden of diabetes management?
- How does once-weekly insulin affect glucose control and stability?
- What barriers threaten long-term persistence?
- What additional support do Awiqli patients need?
- Will patients continue using Awiqli long-term?
About First Look
‘First Look’ is syndicated research that brings new product experiences to life.
It provides timely insights from authentic early adopters giving unprecedented access to many recently launched diabetes products each year.
First Look provides insights on the delivery of functional and emotional benefits. It highlights the successes and pitfalls of product adoption and the underlying reasons.
Our customers use our First Look data services for:
- Commercial strategy
- Competitive intelligence
- Forecasting and market sizing
- Patient segmentation
- Brand positioning and messaging
- HCP education
- Patient support programs
- Product roadmap decisions
The current First Look portfolio includes:
- Medtronic InPen
- FreeStyle Libre 3
- Medtronic 780G
- Tandem Remote Bolus
- Omnipod 5
- Lilly Mounjaro
- iLet Bionic Pancreas
- Tandem Mobi
- Sequel twiist
- Awiqli
Do You Have Questions
About Diabetes Research?
We Have Answers.
This research excerpt is just the tip of the iceberg. dQ&A has decades of experience across the United States, Canada, and Europe. If you drive critical diabetes research decisions in your organization, dQ&A is the diabetes insight partner that can get the answers you need.
